In part 2 of a 3-part series, read about the new recommendations and the dMMR/MSI-H, TMB, and NTRK fusion biomarkers.
- Biomarkers to Guide MBC Treatment Decisions: PIK3CA, BRCA1/BRCA2, and PD-L1/PD-1
- Lobular Breast Cancer Metastasis: Highlighting the Researchers
- Breast Cancer Lung Metastasis: Highlighting the Experts
- Breast Cancer Liver Metastasis: Highlighting the Experts
- Breast Cancer Bone Metastasis: Highlighting the Experts
- Breast Cancer Brain Metastasis: Highlighting the Experts
- Why Do Some People Have an Exceptional Response When Being Treated for MBC?
- Why Does The Same Drug Work Differently In Different People?
- Male MBC Treatment And Clinical Trials
- MBC and NED
- Treatment Strategies for Triple-Positive MBC
- Lobular Metastatic Breast Cancer
- Immunotherapy Resistance
- Lymphodepletion in Cancer Immunotherapy
- Local Therapies for Liver Mets
- Side Effects of Radiation Therapy for Brain Mets
- Screening for Breast Cancer Brain Metastases
- Circulating Tumor Cell Testing
- What is Next-Generation Sequencing?
- Diagnosing & Treatment of Bone Metastases
- Genetic vs. Genomic Testing
- More Men Needed in Breast Cancer Trials
- Should You Get A Second Opinion?
- Best of From the Experts (2018-2019)
- Treatment Guidelines for Metastatic Breast Cancer
- The Future of Metastatic Breast Cancer Treatment
- Palliative Care
- Learn From Home With a Webinar
- What is CAR-T Therapy?
- Managing Lymphedema
SEARCH OUR SITE
for past articles or specific information.